Synthon Biopharmaceuticals has reported positive early pre-clinical results of its second generation HER2-antibody-drug conjugate (ADC).

The research revealed that when HER2-ADC was dosed alone, a complete tumour remission was induced in several xenograft models such as primary human breast cancer and non-small-cell lung cancer.

Toxicity experiments have discovered the improved therapeutic index with at least one order of magnitude compared to other armed antibodies and significant safety profile of HER2-ADC.

Synthon chief scientific officer Dr Marco Timmers said the company’s first ADC program includes the HER2-binding antibody trastuzumab.

"The primary objective is to develop a broad therapeutic spectrum by targeting tumours that over-express HER2, such as metastatic breast cancer and non-small-cell lung cancer," Timmers said.

"As a result of our unique linker-drug technology, this ADC program is delivering on its promise and giving us exciting preclinical results with the opportunity to become a Best-in-Class therapy."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The ADC linker-drug technology based on duocarmycin analogs connects the antibody to the duocarmycin drug, causing elevated stability in circulation while inducing efficient cytotoxin release in the tumour cell.

Synthon anticipates advancing the drug candidate into clinical trials in 2014.

The company has opened a new GMP facility in Nijmegen, the Netherlands, to produce ADCs for Phase III trials and early launches.

"We strongly believe that advancing this second generation ADC technology will lead to a new class of effective, targeted medicines in oncology. Our GMP plant will also accelerate future patient access to oncology products based on this pioneering technology," Timmers said.